埃克替尼治疗晚期非小细胞肺癌的系统评价
x

请在关注微信后,向客服人员索取文件

篇名: 埃克替尼治疗晚期非小细胞肺癌的系统评价
TITLE:
摘要: 目的:系统评价埃克替尼治疗晚期非小细胞肺癌(NSCLC)的疗效和安全性,以为临床提供循证参考。方法:计算机检索PubMed、EMBase、Cochrane图书馆、中国生物医学文献数据库、中国期刊全文数据库、中文科技期刊数据库和万方数据库,收集埃克替尼(试验组)对比吉非替尼或厄洛替尼(对照组)治疗晚期NSCLC的随机对照试验(RCT),对符合纳入标准的临床研究进行资料提取,并采用Cochrane系统评价员手册5.1.0进行质量评价后,采用Rev Man 5.0统计软件进行Meta分析。结果:共纳入5项RCT,合计513例患者。Meta分析结果显示,两组患者有效率[OR=1.19,95%CI(0.79,1.78),P=0.40]、疾病控制率[OR=1.01,95%CI(0.69,1.50),P=0.94]、腹泻发生率[OR=0.68,95%CI(0.45,1.03),P=0.07]比较,差异均无统计学意义;试验组患者皮疹发生率显著低于对照组,差异有统计学意义[OR=0.69,95%CI(0.48,0.99),P=0.04]。结论:埃克替尼治疗晚期NSCLC的疗效与吉非替尼或厄洛替尼相当,但皮疹的发生率低于吉非替尼或厄洛替尼。
ABSTRACT: OBJECTIVE:To evaluate the clinical efficacy and safety of icotinib in the treatment of advanced non-small cell lung cancer (NSCLC), andprovide evidence-based reference for clinic. METHODS:Retrieved from PubMed, EMBase, Cochrane Library, CBM, CJFD and Wanfang database, randomized controlled trials (RCT) about icotinib(test group) versus gefitinib or erlotinib (control group)in the treatment of advanced NSCLC. Meta-analysis was performed by using Rev Man 5.0 software after data extractions and quality evaluation with Cochrane 5.1.0 systematic review manuals. RESULTS: Totally 5 RCT were enrolled, involving 513 patients. Results of Meta-analysis showed there were no significant differences in the total effective rate [OR=1.19,95%CI(0.79,1.78),P=0.40], the disease control rate[OR=1.01,95%CI(0.69,1.50),P=0.94] and the incidence of diarrhea [OR=0.68,95%CI(0.45,1.03),P=0.07] between 2 groups; the incidence of rash in test group was significantly lower than control group, the difference was statistically significant [OR=0.69,95%CI(0.48,0.99),P=0.04]. CONCLUSIONS: The clinical efficacy of icotinib versus gefitinib or erlotinib in the treatment of NSCLC is equivalent, but it can reduce the incidence of rash.
期刊: 2016年第27卷第9期
作者: 旷琛,陈敏,毛棉,蒋学华
AUTHORS: KUANG Chen,CHEN Min,MAO Mian,JIANG Xuehua
关键字: 埃克替尼;吉非替尼;厄洛替尼;非小细胞肺癌;系统评价
KEYWORDS: Icotinib; Gefitinib; Erlotinib; Non-small cell lung cancer; Systematic review
阅读数: 356 次
本月下载数: 6 次

* 注:未经本站明确许可,任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作!